New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)

被引：26

作者：

Chen, Jing ^{[1
]}

Glasser, Chana L. ^{[2
]}

机构：

[1] Hackensack Univ Med Ctr, Div Pediat Hematol Oncol, Hackensack, NJ 07601 USA

[2] NYU Winthrop Hosp, Div Pediat Hematol Oncol, Mineola, NY 11501 USA

来源：

CHILDREN-BASEL | 2020年 / 7卷 / 02期

关键词：

acute myeloid leukemia; antibody drug conjugate; ANTIBODY-DRUG CONJUGATE; OPEN-LABEL; GEMTUZUMAB OZOGAMICIN; MOLECULAR LANDSCAPE; MDM2; ANTAGONISTS; INHIBITION; CHEMOTHERAPY; MULTICENTER; ACTIVATION; YOUNGER;

D O I：

10.3390/children7020012

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. Prognosis for this subgroup of children with relapsed/refractory AML remains poor. It is well known that the ceiling of chemotherapy intensification has been reached, limited by acute and chronic toxicity, necessitating alternative treatment approaches. In the last several years, our improved understanding of disease biology and critical molecular pathways in AML has yielded a variety of new drugs to target these specific pathways. This review provides a summary of antibody drug conjugates (ADCs), small molecule inhibitors, and tyrosine kinase inhibitors with an emphasis on those that are currently under clinical evaluation or soon to open in early phase trials for children with relapsed/refractory AML.

引用

页数：15

共 91 条

[71] Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012 [J].

Rasche, Mareike ;

Zimmermann, Martin ;

Borschel, Lisa ;

Bourquin, Jean-Pierre ;

Dworzak, Michael ;

Klingebiel, Thomas ;

Lehrnbecher, Thomas ;

Creutzig, Ursula ;

Klusmann, Jan-Henning ;

Reinhardt, Dirk .

LEUKEMIA, 2018, 32 (10) :2167-2177

[72] Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence [J].

Rashidi, Armin ;

DiPersio, John F. .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (01) :40-51

[73] Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia [J].

Ravandi, Farhad ;

Cortes, Jorge E. ;

Jones, Daniel ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Konopleva, Marina Y. ;

O'Brien, Susan ;

Estrov, Zeev ;

Borthakur, Gautam ;

Thomas, Deborah ;

Pierce, Sherry R. ;

Brandt, Mark ;

Byrd, Anna ;

Bekele, B. Nebiyou ;

Pratz, Keith ;

Luthra, Rajyalakshmi ;

Levis, Mark ;

Andreeff, Michael ;

Kantarjian, Hagop M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1856-1862

[74] Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial [J].

Raza, Azra ;

Jurcic, Joseph G. ;

Roboz, Gail J. ;

Maris, Michael ;

Stephenson, Joseph J. ;

Wood, Brent L. ;

Feldman, Eric J. ;

Galili, Naomi ;

Grove, Laurie E. ;

Drachman, Jonathan G. ;

Sievers, Eric L. .

LEUKEMIA & LYMPHOMA, 2009, 50 (08) :1336-1344

[75] Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial [J].

Rollig, Christoph ;

Serve, Hubert ;

Huettmann, Andreas ;

Noppeney, Richard ;

Mueller-Tidow, Carsten ;

Krug, Utz ;

Baldus, Claudia D. ;

Brandts, Christian H. ;

Kunzmann, Volker ;

Einsele, Hermann ;

Kraemer, Alwin ;

Schaefer-Eckart, Kerstin ;

Neubauer, Andreas ;

Burchert, Andreas ;

Giagounidis, Aristoteles ;

Krause, Stefan W. ;

Mackensen, Andreas ;

Aulitzky, Walter ;

Herbst, Regina ;

Haenel, Mathias ;

Kiani, Alexander ;

Frickhofen, Norbert ;

Kullmer, Johannes ;

Kaiser, Ufrich ;

Link, Hartmut ;

Geer, Thomas ;

Reiche, Albert ;

Junghanss, Christian ;

Repp, Roland ;

Heits, Frank ;

Duerk, Heinz ;

Hase, Jana ;

Klut, Ina-Maria ;

Illmer, Thomas ;

Bornhaeuser, Martin ;

Schaich, Markus ;

Parmentier, Stefani ;

Goerner, Martin ;

Thiede, Christian ;

von Bonin, Malte ;

Schetelig, Johannes ;

Kramer, Michael ;

Berdel, Welfgang E. ;

Ehninger, Gerhard .

LANCET ONCOLOGY, 2015, 16 (16) :1691-1699

[76]

Sallman D.A., 2019, PHASE 2 RESULTS APR

[77]

Shaikh MF, 2016, ANN CLIN LAB SCI, V46, P627

[78] Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia [J].

Shukla, Neerav ;

Wetmore, Cynthia ;

O'Brien, Maureen M. ;

Silverman, Lewis B. ;

Brown, Patrick ;

Cooper, Todd M. ;

Thomson, Blythe ;

Blakemore, Stephen J. ;

Daigle, Scott ;

Ben Suttle ;

Waters, Nigel J. ;

Krivstov, Andrei V. ;

Armstrong, Scott A. ;

Ho, Peter T. ;

Gore, Lia .

BLOOD, 2016, 128 (22)

[79] Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy [J].

Steelman, L. S. ;

Franklin, R. A. ;

Abrams, S. L. ;

Chappell, W. ;

Kempf, C. R. ;

Baesecke, J. ;

Stivala, F. ;

Donia, M. ;

Fagone, P. ;

Nicoletti, F. ;

Libra, M. ;

Ruvolo, P. ;

Ruvolo, V. ;

Evangelisti, C. ;

Martelli, A. M. ;

McCubrey, J. A. .

LEUKEMIA, 2011, 25 (07) :1080-1094

[80] The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia [J].

Stein, Eytan M. ;

Garcia-Manero, Guillermo ;

Rizzieri, David A. ;

Tibes, Raoul ;

Berdeja, Jesus G. ;

Savona, Michael R. ;

Jongen-Lavrenic, Mojca ;

Altman, Jessica K. ;

Thomson, Blythe ;

Blakemore, Stephen J. ;

Daigle, Scott R. ;

Waters, Nigel J. ;

Suttle, A. Benjamin ;

Clawson, Alicia ;

Pollock, Roy ;

Krivtsov, Andrei ;

Armstrong, Scott A. ;

DiMartino, Jorge ;

Hedrick, Eric ;

Lowenberg, Bob ;

Tallman, Martin S. .

BLOOD, 2018, 131 (24) :2661-2669

← 1 2 3 4 5 6 7 8 9 10 →